(Q35097989)

6 August 2017

1 reference

title

Overview of bladder cancer trials in the Cancer and Leukemia Group B. (English)

1 reference

Cancer and Leukemia Group B

6 August 2017

1 reference

8

object named as

Cancer and Leukemia Group B

1 reference

6 August 2017

Eric J Small

1

1 reference

6 August 2017

Susan Halabi

2

1 reference

6 August 2017

Guido Dalbagni

3

1 reference

6 August 2017

Raj Pruthi

4

1 reference

6 August 2017

George Phillips

5

1 reference

6 August 2017

Martin Edelman

6

1 reference

6 August 2017

Dean Bajorin

7

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

6 August 2017

1 reference

6 August 2017

97

1 reference

6 August 2017

2090-2098

1 reference

6 August 2017

8 Suppl

1 reference

Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder

6 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

Prognostic value of epidermal growth factor-receptor, T138 and T43 expression in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

21 January 2018

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

The epidermal growth factor receptor and the prognosis of bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Protein modules and signalling networks

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Gene amplification detected in carcinoma cells from human urinary bladder washings by the polymerase chain reaction method

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Expression of epidermal growth factor receptor in urinary bladder cancer metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Carboplatin-based chemotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Single agent paclitaxel as a first-line therapy in advanced urothelial carcinoma: its efficacy and safety in patients even with pretreatment renal insufficiency

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

HER-2/neu signal transduction in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

c-erbB-2 oncoprotein expression in primary human tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Interrelationship between expression of p53, proliferating cell nuclear antigen and c-erbB-2 in bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11299

7 January 2021

Identifiers

DOI

10.1002/CNCR.11299

1 reference

6 August 2017

1 reference